Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
August 2020
-
Press release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164… -
Press release
Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on… -
In The News
Supply chain organization during the COVID-19 pandemic
Balancing priorities of combating the crisis and ongoing trials. -
Featured News
50 Climate Leaders
At Novartis, we aim to be a leader in environmental sustainability and a catalyst for positive change both in our own operations and in our supply chain.
-
Press release
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with… -
In The News
The coronavirus is giving health and pharma companies a chance to woo tech talent
Novartis Chief Digital Officer Bertrand Bodson says tech professionals don’t need a background in biology to switch industries. -
Press release
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported… -
Story Discovery
Building collaborations to fight a pandemic
Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.
-
Ad hoc release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple… -
Ad hoc release
Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent
Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our… -
Featured News
Novartis appoints Marc Boutin as Global Head of Patient Engagement & Advocacy
-
Story Access to Healthcare
Ensuring medicine supply to patients during COVID-19
Read how two sites within the Novartis Technical Operations (NTO) network ensured business continuity at scale and speed in the midst of the COVID-19 pandemic.